The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

Manish A.  Shah

Consulting or Advisory Role - Lilly

Research Funding - Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst)

Jean-Philippe  Metges

Honoraria - Lilly; Merck; Novartis; Sanofi

Patrick Youngwhan  Chun

Employment - Gilead Sciences; Merck Sharp & Dohme

Stock and Other Ownership Interests  - Gilead Sciences

Travel, Accommodations, Expenses - Gilead Sciences

Victoria  Smith

Employment - Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences

Julia D.  Maltzman

Employment - Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences

Zev A.  Wainberg

Consulting or Advisory Role - Amgen; Array BioPharma; Five Prime Therapeutics; Sirtex Medical

Speakers' Bureau - Genentech

Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)

Travel, Accommodations, Expenses - Amgen; Genentech